Hormonal regulation of β2-adrenergic receptor level in prostate cancer

Prostate

Volumn 68, Issue 10, 2008, Pages 1133-1142

  Ramberg, Håkon ^a   Eide, Turid ^a   Krobert, Kurt Allen ^b   Levy, Finn Olav ^b   Dizeyi, Nishtman ^c   Bjartell, Anders S ^c,d   Abrahamsson, Per Anders ^c   Taskén, Kristin Austlid ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bicalutamide; LNCaP cells; Triiodothyronine

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BICALUTAMIDE; CYCLIC AMP; LIOTHYRONINE; MESSENGER RNA; THYMIDINE; ANDROGEN; ANDROGEN RECEPTOR; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BIOPSY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS; BIOPSY; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; TRIIODOTHYRONINE; UP-REGULATION;

EID: 45749085708     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20778     Document Type: Article

References (37)

1. Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther 2005;5:63-74.
2. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 2005;280:11583-11589.
3. Morita K, Arimochi H, Tsuruo Y. Adrenergic activation of steroid 5alpha-reductase gene expression in rat C6 glioma cells: Involvement of cyclic amp/protein kinase A-mediated signaling pathway. J Mol Neurosci 2004;22:205-212.
4. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999;59:3821-3830.
5. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005;47:147-155.
6. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000;42:274-279.
7. McVary KT, McKenna KE, Lee C. Prostate innervation. Prostate Suppl 1998;8:2-13.
8. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004;64:6082-6090.
9. Goepel M, Wittmann A, Rubben H, Michel MC. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 1997;25:199-206.
10. Marchetti B, Poulin R, Plante M, Labrie F. Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J Steroid Biochem 1988;31:411-419.
11. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-1013.
12. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-2581.
13. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-5299.
14. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 2002;3: SOFTWARE0003.
15. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-227.
16. Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO. The cloned human 5-HT7 receptor splice variants: A comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol 2001;363:620-632.
17. Erichsen A, Levy FO, Golf S, Hansson V. A transplantable rat Leydig cell tumor-5. Cellular localization of beta-adrenergic and prostaglandin receptors and their effects on testosterone production. J Steroid Biochem 1988;31:41-48.
18. Brown BL, Albano JD, Ekins RP, Sgherzi AM. A simple and sensitive saturation assay method for the measurement of adenosine 3′5′-cyclic monophosphate. Biochem J 1971;121:561-562.
19. Bjoro T, Ostberg BC, Sand O, Gordeladze J, Iversen JG, Torjesen PA, Gautvik KM, Haug E. Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH4C1) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca2+. Mol Cell Endocrinol 1987;49:119-128.
20. Ikonen T, Palvimo JJ, Janne OA. Interaction between the amino-and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 1997;272:29821-29828.
21. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 2006;169:2199-2208.
22. Dizeyi N, Bjartell A, Hedlund P, Tasken KA, Gadaleanu V, Abrahamsson PA. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 2005;47:895-900.
23. Lennon G, Auffray C, Polymeropoulos M, Soares MB. The I.M.A.G.E. Consortium: An integrated molecular analysis of genomes and their expression. Genomics 1996;33:151-152.
24. Wang G, Jones SJ, Marra MA, Sadar MD. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene 2006;25:7311-7323.
25. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274:7777-7783.
26. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277:29304-29314.
27. Kvissel AK, Ramberg H, Eide T, Svindland A, Skalhegg BS, Tasken KA. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal 2007;19:401-409.
28. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-Cell translocation gene 2. Prostate 2008;68:610-619.
29. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol 1995;109:105-111.
30. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, Young CY. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology 1999;140:1665-1671.
31. Choi KC, Oh SY, Kang HB, Lee YH, Haam S, Kim HI, Kim K, Ahn YH, Kim KS, Yoon HG. The functional relationship between corepressor N-CoR and SMRT in mediating transcriptional repression by thyroid hormone receptor alpha. Biochem J 2007;411:19-26.
32. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, Mills IG. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007;8:871-878.
33. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg AN. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005;280:6511-6519.
34. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschiaden F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-2749.
35. Sastry KS, Karpova Y, Prokopovich S, Smith AJ, Essau B, Gersappe A, Carson JP, Weber MJ, Register TC, Chen YQ, Penn RB, Kulik G. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 2007;282:14094-14100.
36. Prowatke I, Devens F, Benner A, Grone EF, Mertens D, Grone HJ, Lichter P, Joos S. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer 2007;96:82-88.
37. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004;15:535-541.